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 2. 
Abstract 24 
Background: With accumulating knowledge on osteoarthritis development, the next step is to 25 
focus on possibilities for primary prevention. 26 
Methods: In a 2x2 factorial design, the effects of a diet and exercise program and of oral 27 
glucosamine sulphate (double blind and placebo-controlled) on the incidence of knee 28 
osteoarthritis were evaluated in a high-risk group of 407 middle-aged women with a BMI ≥ 27 29 
kg/m2 without clinical signs of knee osteoarthritis at baseline (ISRCTN 42823086). Primary 30 
outcome was the incidence of knee osteoarthritis, defined as Kellgren & Lawrence grade ≥ 2, 31 
joint space narrowing of ≥ 1.0 mm or clinical knee osteoarthritis (clinical and radiographic 32 
American College of Rheumatology-criteria) after 2.5 years. 33 
Results: After 2.5 years, only 10% of all subjects were lost to follow-up and 17% of all knees 34 
showed incident knee osteoarthritis. Accounting for the significant interaction between the 35 
interventions, no significant main effect of either intervention was found. Independently, both 36 
interventions alone showed indications of reduced knee osteoarthritis incidence (OR 0.69; 95% 37 
CI: 0.39 - 1.21 for the diet and exercise program and 0.60; 95% CI: 0.31 - 1.12 for the 38 
glucosamine intervention). These effects were neutralized in subjects receiving both 39 
interventions (OR 0.97; 95% CI: 0.55 - 1.71). 40 
Conclusions: No significant main effects of the diet and exercise program and of glucosamine 41 
sulphate were found on incident knee osteoarthritis. Nevertheless, this trial provides valuable 42 
insights for future trial design for preventive osteoarthritis studies.  43 
 3. 
Introduction  44 
According to the World Health Organisation, more than 10% of people aged 60 and over suffer 45 
from osteoarthritis  worldwide 1. Thereby it is the most common joint disease in this age range 46 
2. Over the last decades, numerous longitudinal studies on risk factors for onset of 47 
osteoarthritis have been performed 3, 4. These studies have led to the identification of a wide 48 
variety of risk factors; mainly focusing on knee osteoarthritis. With this accumulated 49 
knowledge, primary prevention should be considered 5, 6. Several studies indicate that weight 50 
loss in overweight or obese individuals could prevent knee osteoarthritis 3, 7-9. In an 51 
observational cohort, it was calculated that if women with a body mass index (BMI) ≥ 25 kg/m2 52 
would reduce their BMI with 2 units (~ 5 kg), the risk for developing knee osteoarthritis would 53 
be reduced substantially (OR = 0.41) 8. The direct effects of weight reduction (primary 54 
prevention) on subsequent knee osteoarthritis development have never been studied.  55 
Glucosamine has been studied for the treatment of osteoarthritis patients , but no 56 
efficacy has been proven in studies with adequate allocation concealment or in investigator led 57 
studies 10. Literature suggests larger effects of glucosamine over placebo when used in an early 58 
phase of the disease 11 and especially in the knee joint 12. Glucosamine has never been tested 59 
for its preventive effects. Since all forms of oral glucosamine have shown to produce no side 60 
effects over placebo, even after long-term use 13, investigation of the preventive effect of 61 
glucosamine on incident knee osteoarthritis seems safe and worthwhile.  62 
The objective of the present study was to evaluate the effect of a tailored diet and 63 
exercise program, aimed to reduce weight, and of oral crystalline glucosamine sulphate on 64 
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incidence of knee osteoarthritis in a high risk group of overweight women between 50 and 60 65 
years, free of clinical knee osteoarthritis at baseline. 66 
 67 
Method 68 
The PROOF study (PRevention of knee Osteoarthritis in Overweight Females, ISRCTN 69 
42823086) was approved by the Medical Ethics Committee of Erasmus MC University Medical 70 
Centre in 2005. The manuscript has been written according to the CONSORT Statement 71 
guidelines 14. Additional extensive method sections are provided in the Appendix. 72 
Setting and Participants Women aged 50 to 60, with a BMI ≥ 27 kg/m2, free of knee 73 
osteoarthritis (clinical American College of Rheumatology (ACR)-criteria 15), not treated for knee 74 
complaints or using walking-aids, free of MRI-contraindications, without rheumatic diseases, 75 
master the Dutch language and not using glucosamine were recruited trough their general 76 
practitioner (Appendix). All women eligible and willing to participate were invited for baseline 77 
measurements (July 2006 – May 2009). 78 
Physical Examination At baseline and after 2.5 years follow-up, body weight and height were 79 
measured and both hands were examined for Heberden's nodes.  80 
Radiography Semi-flexed posterior-anterior knee radiographs were taken at baseline and 81 
follow-up according to the MTP protocol 16 and scored using the Kellgren & Lawrence (K&L) 82 
criteria 17. Minimal joint space width was measured by visual reading for each tibiofemoral 83 
compartment 18. Medial knee alignment angle was assessed for all knees 19 (Appendix). 84 
Questionnaires At baseline and every 6 months, participants filled in questions on the number 85 
of days with knee pain, activity level (SQUASH 20), co-interventions, and quality of life (EuroQol 86 
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21). At baseline, 12 months and 30 months, knee complaints, Knee injury and Osteoarthritis 87 
Outcome Score (KOOS) questionnaire 22, menopausal status, and co-morbidities were 88 
additionally assessed.  89 
Randomization After informed consent procedure according to the declaration of Helsinki and 90 
subsequent baseline measurements, subjects were randomized using consecutive case 91 
numbers. For the diet and exercise program, subjects were randomized 1:1 using block 92 
randomisation with block size 20. A research assistant, not involved in the trial, provided a 93 
sealed envelope that was opened by the subject in the presence of the researcher. Allocation to 94 
glucosamine or placebo (double-blind) was also done one-on-one using a blocked 95 
randomization list with block size 20 (see below). 96 
Home Visits Every 6 months a home visit was planned to measure body weight , check the 97 
questionnaire for missing data, provide the participant with a new batch of study drugs, and 98 
retrieve the remainder of the previous batch for objective compliance calculation. 99 
Diet and Exercise Program  A detailed description of the diet and exercise program is given 100 
elsewhere 23. In short, subjects in the intervention group were referred to a local dietician who 101 
set goals regarding nutritional habits and physical activity patterns in agreement with the 102 
participant, using Motivational Interviewing techniques 24. Thereafter a tailor made strategy 103 
and an individual planning were composed to achieve these goals. Additionally, subjects were 104 
invited to join a weekly physical exercise class (12 to 15 participants) of one hour for twenty 105 
weeks, supervised by a local physical therapist. A variety of low impact sports and exercises, 106 
such as Nordic walking, aqua jogging and dancing, were offered in order to regain pleasure in 107 
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physical activity and find activities for long-term continuation. The control group was not 108 
offered an intervention. 109 
Crystalline Glucosamine Sulphate versus Placebo  When designing this trial, high drop-out 110 
rates in the control group of the diet and exercise program were feared. To prevent this, the 111 
glucosamine sulphate vs. placebo intervention was introduced, in order to provide all subjects 112 
with an intervention and hopefully avoid high drop-out rates.  Subjects and research staff were 113 
blinded for allocation throughout the study. All study drugs were provided in identical 114 
packaging by Rottapharm Madaus, who was not involved in study design, data collection, or 115 
statistical analyses. Subjects were asked to consume one sachet (1500 mg powder) per day for 116 
the total follow-up period.  117 
Outcome Measures Predefined primary outcome was the difference between groups on the 118 
incidence of knee osteoarthritis, defined as incidence of either K&L ≥ 2, clinical knee 119 
osteoarthritis (clinical and radiographic ACR-criteria 15) or joint space narrowing of ≥ 1.0 mm in 120 
the medial or lateral compartment. Secondary outcomes were quality of life, Western Ontario 121 
and McMaster Universities Osteoarthritis Index (WOMAC) pain and WOMAC function scores 122 
(calculated from KOOS, ranging 0-100 with 0 being no pain/no functional limitations), weight 123 
loss, occurrence of osteoarthritis MRI features, and increase in bone and cartilage degeneration 124 
markers. Given the complexness of the MRI and degeneration marker evaluations, these 125 
outcomes will not be presented here.  126 
Sample Size The study was powered to show an incidence reduction from 20% in the diet and 127 
exercise program control group and in the placebo group to 10% in the diet and exercise 128 
program intervention and the glucosamine group (Appendix). No interaction between the 129 
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interventions was assumed. Based on our previous 2-year osteoarthritis trial 25, we accounted 130 
for 10% lost to follow-up. Therefore, two groups of 200 subjects would be appropriate (one-131 
sided testing, alpha = 0.05, beta = 0.80). 132 
Statistical Analysis Intention To Treat (ITT) analyses on all available data of all knees of all 133 
randomized participants served as primary analyses. The interaction between both 134 
interventions was determined using Generalized Estimating Equations (GEE), adjusted for 135 
confounding variables. Next, the effects of the diet and exercise program and the glucosamine 136 
vs. placebo intervention were determined using GEE, adjusted for confounding variables. In 137 
case of a significant interaction between the interventions, these analyses will be performed 138 
over four groups, with subjects in the diet and exercise program control group receiving 139 
placebo as reference (Appendix). 140 
For the pre-defined Per Protocol (PP) analyses, the ITT analyses were rerun, between 141 
those subjects compliant to the diet and exercise program (≥ 6 dietary consultations and ≥ 7 142 
exercise classes) and those randomized to the control group and, separately, in those with an 143 
objective compliance calculation ≥ 75% . A sensitivity analysis excluding all knees fulfilling one 144 
of the criteria of the primary outcome at baseline was performed, and all analyses were 145 
repeated on subject level. All analyses were performed using PASW statistics version 20.0 (SPSS 146 
Inc., Chicago, IL).  147 
Available secondary outcomes were analysed using a linear mixed model estimated by 148 
restricted maximum likelihood (SAS 9.2, SAS Institute Inc., Cary, NC). A p-value < 0.05 was 149 
defined as statistically significant for all analyses. Randomization code for glucosamine vs. 150 
placebo intervention was broken after all analyses were completed. 151 
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 152 
Results 153 
In total, 6691 women were contacted by fifty general practitioners. Eventually, 407 women 154 
were invited for baseline measurements and were randomised (24.8% to the diet and exercise 155 
program intervention/placebo group and 25.1% to each of the other groups, see Figure 1). 156 
Mean age was 55.7 ± 3.2 years and mean BMI was 32.4 ± 4.3 kg/m2 (Table 1). After 2.5 years, 157 
forty-one women (10.1%) were lost to follow-up. Of these, thirty-six women were unwilling; 158 
two withdrew because of side effects; one was unattainable; two died in the course of the 159 
study. One woman died shortly after study ending (all deaths not related to study drugs).  160 
Joint space narrowing (ICC 0.67 – 0.76) was found medially in 5% and laterally in 6% of all 161 
knees. Incidence of K&L-grade ≥ 2 was found in 4% of all knees (kappa 0.6). Six per cent of all 162 
knees showed incident clinical osteoarthritis. Combined into the primary outcome, 135 knees 163 
(17%) showed incident knee osteoarthritis (in 28% of all women). Despite the fact that all 164 
included subjects were free of clinical knee osteoarthritis at initial screening, 3.9% of all knees 165 
fulfilled the ACR criteria at baseline and 6.6% showed K&L-grade 2 after detailed assessment of 166 
the radiographs.. Multivariately, only K&L grade was associated with the primary outcome.  167 
Intention To Treat Analyses The ITT analyses showed a significant interaction (p = 0.04). Hence, 168 
the effects of one intervention depended on the allocation of the other intervention and four 169 
groups had to be analysed separately (Table 2).  170 
Diet and Exercise Program 28% of the 203 women randomized to the diet and exercise 171 
program were compliant (equally distributed over placebo and glucosamine groups). Compliant 172 
women had a mean weight reduction of 1.4 ± 5.2 kg at follow-up versus 0.0 ± 6.7 kg in the 173 
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control group. At 6 and 12 months, the number of participants fulfilling the predefined target of 174 
5 kg or 5% weight reduction was significantly higher in the intervention group (14% vs. 6% at 6 175 
months, p = 0.01; 17% vs. 10% at 12 months, p = 0.04). Eventually, 63 women (15%) met this 176 
target at 30 months. Detailed effects of the diet and exercise program can be found elsewhere 177 
23. 178 
PP analyses showed a significant interaction with the glucosamine vs. placebo 179 
intervention (p = 0.01). Incidence of knee osteoarthritis was found in 19%, 13%, 9% and 23% of 180 
the knees of subjects randomized to the control group with placebo, with glucosamine, subjects 181 
compliant to the diet and exercise program with placebo and those with glucosamine, 182 
respectively (Table 3).  183 
Oral Glucosamine Sulphate versus Placebo A total of 291 adverse events were reported by a 184 
total of 118 women, equally divided between glucosamine and placebo group (Chi2 test: p = 185 
0.23). All reported serious adverse events (26 by 25 women) were classified as not related to 186 
study drug and also equally divided between groups (Chi2 test: p = 0.26). After study ending, 187 
17% of the women in the placebo group and 15% of the women in the glucosamine group were 188 
convinced they had received glucosamine. The majority of all women (52% in the placebo group 189 
and 46% in the glucosamine group) were convinced they received placebo (Chi2 test: p = 0.24). 190 
None of the involved researchers or participants were unblinded during the trial. In total, 250 191 
women were compliant (66% of the placebo group, 57% of the glucosamine group).  192 
PP analyses showed no interaction between both interventions (p = 0.17). Incidence of 193 
knee osteoarthritis occurred in 20% of the knees of the women compliant to the placebo (21% 194 
in control group and 18% in the diet and exercise program intervention group) and in 21% (17% 195 
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in control group and 24% in the diet and exercise program intervention group) of the knees of 196 
women compliant to glucosamine (adjusted OR 0.99 [0.61 – 1.63]). 197 
Secondary outcome Secondary outcomes are represented in Appendix Figures 1-4. There was 198 
only a statistically significant difference between the diet and exercise program intervention 199 
and control group on actual weight loss (p = 0.04). Detailed analyses showed a significant 200 
difference in weight loss at 6 months (p < 0.01) and 12 months (p = 0.01). Also in PP analyses, 201 
only the effect of the diet and exercise program on actual weight loss was statistically 202 
significant in favour of the intervention group (p = 0.01), with statistically significant differences 203 
in weight loss at 6 months (p < 0.01), 12 months (p < 0.01), 18 months (p = 0.02), and 24 204 
months (p = 0.04). 205 
Sensitivity analysis When excluding all knees fulfilling one of the items of the primary outcome 206 
at baseline, the interaction between both interventions was borderline significant in the ITT 207 
analyses (p = 0.10) and statistically significant in the PP analysis for the diet and exercise 208 
program (p = 0.03). See Appendix Tables 1 and 2. In the sensitivity analyses at subject level, the 209 
interaction between both interventions was also borderline significant in ITT analyses (p = 0.12) 210 
and statistically significant in PP analyses for the diet and exercise program (p < 0.01). See 211 
Appendix Table 3 and 4. 212 
 213 
Discussion 214 
This study presents the first ever preventive randomized trial on osteoarthritis 215 
worldwide. The diet and exercise program and the glucosamine sulphate intervention showed 216 
no significant main effects on the incidence of knee osteoarthritis after 2.5 years. However, due 217 
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to the unexpected significant interaction, these analyses were slightly underpowered. The fact 218 
that the interaction became even stronger in subjects compliant to the diet and exercise 219 
program, was found in sensitivity analyses, and at subject level, indicates a true interaction 220 
between the interventions.  221 
This preventive randomised trial focused on subjects with high risk of developing knee 222 
osteoarthritis and used a combined outcome measure to make a trial in such a slowly 223 
progressing disease feasible over a relative short time period. This combination of radiographic 224 
and clinical measures of knee osteoarthritis into the primary outcome improves the ability to 225 
determine the preventive effects of the studied interventions 5, although one misses the 226 
detailed insight in the development of the disease. Explorative evaluation of the separate items 227 
of the primary outcome confirmed the pattern found in the main analyses, but longer follow-up 228 
is needed to statistically test these outcomes separately given the naturally slow disease 229 
development.  230 
Although we found no significant main effects of the diet and exercise program and the 231 
glucosamine vs. placebo intervention on primary outcomes, the interaction between the 232 
interventions did show several interesting results. Where glucosamine sulphate reduced 233 
osteoarthritis incidence numbers in the group not undergoing the diet and exercise program 234 
(13% vs. 19%; adjusted OR 0.59 [0.31 – 1.12]), osteoarthritis incidence was increased in the 235 
glucosamine sulphate group within the diet and exercise program intervention group (20 vs. 236 
15%; adjusted OR 1.44 [0.83 – 2.48]). On the other hand, the diet and exercise program 237 
reduced the incidence numbers within the placebo group (15% vs. 19%; adjusted OR 0.69 [0.39 238 
– 1.21]), but showed an increased OR within the glucosamine sulphate group (20% vs. 13%; 239 
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adjusted OR 1.63 [0.89 – 3.01]). Taking only subject compliant to the diet and exercise program 240 
into account, the effects became even stronger (9% vs. 19%; adjusted OR 0.35 [0.11 – 1.10] 241 
within placebo group and 23% vs. 13%; adjusted OR 2.17 [0.95 – 4.96] within the glucosamine 242 
sulphate group). Although tested in subjects with established knee osteoarthritis, results from 243 
Messier et al. 26 might give some suggestion for the mechanism behind this interaction. Messier 244 
and co-workers found that after a 6 months exercise period, subjects randomized to a 245 
combination of glucosamine/chondroitin decreased in knee flexion strength, whereas subjects 246 
receiving placebo significantly improved their strength 26. These results suggest that 247 
glucosamine might interfere with processes of repair and growth after physical exercise. On the 248 
other hand, a 12 week training program combined with glucosamine sulphate did not show a 249 
difference in knee extension strength over the placebo group in knee osteoarthritis patients 27. 250 
The more sensitive and explorative measures of the MRI and biomarkers, which are being 251 
assessed within the present study, might provide more detailed information on the underlying 252 
mechanism.  253 
For implementation reasons, a very pragmatic design was chosen for the diet and 254 
exercise program. Nevertheless, the intervention had a significant effect on the actual weight 255 
loss during the first year of follow-up and activity levels were higher in the intervention group 256 
throughout the total follow-up period. Thus, despite the relatively low compliance figures, 257 
similar to other physical exercise and diet interventions in overweight and obese individuals 28, 258 
and a short duration, the current diet and exercise program succeeded in a low level change in 259 
lifestyle, also in the ITT population. Contrary to daily practice, the control group was relatively 260 
active . Nearly 90% of all subjects stated to have a preference for the intervention group at 261 
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baseline. For ethical reasons, the control group was not actively refrained from any 262 
interventions on weight loss. After 2.5 years, 18% of all women randomized to the control 263 
group fulfilled the criterion of losing 5 kg or 5% of baseline body weight. Therefore, the effects 264 
of the diet and exercise program found on incident knee osteoarthritis may have been 265 
underestimated. 266 
In conclusion, we showed no significant main effects of the diet and exercise program or 267 
the glucosamine vs. placebo intervention on incidence of knee osteoarthritis over 2.5 years. 268 
These analyses, however, were hampered by an unexpected significant interaction between the 269 
two interventions. The current trial provides many new insights in the possibilities for 270 
prevention of knee osteoarthritis within a high-risk group of middle-aged, overweight women. 271 
The low dropout rate of 10% strengthens results of this first attempt to prevent osteoarthritis in 272 
subject at high risk. The indications for preventive effects of the two interventions separately 273 
and their interaction needs further elaboration.  274 
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Table 1. Distribution and mean (SD) of prognostic variables among the randomized 
intervention arms at baseline. 
 Diet & and Exercise Program 
 Control group Intervention group 
  Placebo Glucosamine Placebo Glucosamine 
N - subjects 102 102 101 102 
   Age (yr) 55.7 (3.3) 55.7 (3.1) 55.7 (3.2) 55.7 (3.1) 
   BMI,  kg/m2 32.6 (4.3) 32.4 (4.6) 32.3 (4.5) 32.1 (3.7) 
   Heberden's nodes         
     uni-lateral 15% 16% 12% 12% 
     bi-lateral 10% 14% 20% 9% 
   Postmenopausal status 70% 68% 66% 67% 
   EuroQol, 0 – 1* 0.90 (0.12) 0.88 (0.13) 0.88 (0.14) 0.90 (0.12) 
   Physical activity** 6992 ± 3807 7210 ± 3827 6719 ± 3961 6333 ± 3228 
   WOMAC, 0 – 100***     
     Pain 5.1 (8.5) 7.1 (11.7) 8.1 (13.3) 6.6 (11.4) 
     Function 5.3 (8.7) 7.1 (12.2) 7.7 (12.2) 5.9 (10.4) 
N – knees 204 204 202 204 
   K&L     
     grade 0 53% 47% 53% 50% 
     grade ≥ 1 46% 53% 46% 50% 
   Minimal JSW     
      medial, mm 4.4 (0.8) 4.4 (0.8) 4.4 (0.8) 4.4 (0.9) 
      lateral, mm 5.9 (1.1) 5.8 ± 0.9 5.8 ± 1.1 6.1 (1.2) 
   Varus alignment 46% 38% 38% 37% 
   Mild symptoms 29% 30% 36% 27% 
   History of knee injury 14% 12% 10% 13% 
* Higher scores represent higher quality of life. ** measured using SQUASH. *** Higher scores 
represent more pain/worse function. JSW: joint space width 
 
 
  
Table(s)
Table 2. Odds ratios from Intention To Treat analyses for the four randomized groups on 
incidence of knee OA. 
 N 
(knees) 
Incident 
knee OA 
OR * 95% CI OR ** 
 
95% CI 
DEP control / placebo 204 19% 1 (reference) 1 (reference) 
DEP control / glucosamine 204 13% 0.610 0.328 – 1.135 0.591 0.313 – 1.118 
DEP intervention / placebo 202 15% 0.695 0.396 – 1.213 0.685 0.389 – 1.208 
DEP intervention / glucosamine 204 20% 1.010 0.579 – 1.763 0.972 0.553 – 1.710 
* unadjusted odds ratio. ** odds ratio adjusted for baseline KL grade (0 vs. ≥ 1). DEP: diet and 
exercise program, OR: odds ratio, CI: confidence interval. 
 
 
Table 3. Odds ratios from Per Protocol analyses on incidence of knee OA. 
 N 
(knees) 
Incident 
knee OA 
OR * 95% CI OR ** 95% CI 
DEP control / placebo 204 19% 1 (reference) 1 (reference) 
DEP control / glucosamine 204 13% 0.610 0.328 – 1.135 0.590 0.310 – 1.122 
Compliant to DEP / placebo 58 9% 0.341 0.109 – 1.063 0.349 0.110 – 1.105 
Compliant to DEP / glucosamine 56 23% 1.220 0.567 – 2.628 1.277 0.594 – 2.747 
* unadjusted odds ratio. ** odds ratio adjusted for baseline KL grade (0 vs. ≥ 1). DEP: diet and 
exercise program, OR: odds ratio, CI: confidence interval. 
 
APPENDIX to ‘Prevention of knee osteoarthritis in overweight females; the first randomized controlled 
trial in OA’osteoarthritis’. 
 
Additional method section 
Setting and Participants Fifty general practitioners in the region of Rotterdam, The Netherlands, sent study 
information and a reply-card to all registered women between 50 and 60 years without major co-morbidities. 
Interested women with a reported BMI ≥ 27 kg/m
2
 were contacted by phone to check all inclusion criteria. 
Besides age and BMI-related inclusion criteria, subjects had to be free of knee OA osteoarthritis according to 
the clinical American College of Rheumatology (ACR)-criteria 
1
, not under treatment for knee complaints, free of 
MRI contraindications, free of rheumatic diseases, not using walking-aids, master the Dutch language and not 
using oral glucosamine for the last 6 months. 
Radiography Semi-flexed posterior-anterior knee radiographs were taken at baseline and follow-up according 
to the MTP protocol 
2
. A trained researcher (MR), blinded for clinical outcomes and treatment assignment, 
scored all radiographs (baseline and follow-up images at once with known sequence) using the Kellgren & 
Lawrence (K&L) criteria 
3
. A random subset of 20% of the radiographs was scored by a second blinded 
researcher (JR) to determine inter-observer variability. Minimal joint space width was measured by visual 
reading with the use of a digital ruler for each tibiofemoral compartment 
4
, using the average score of two 
researchers blinded for clinical outcomes and baseline measurements (JR and BdV). Scores with a difference 
between both readers ≥ 2.0 mm were re-evaluated during a consensus meeting. Medial knee alignment angle 
was assessed by digitally determining the angle between the line from the center of the tibial spines through the 
center of the femoral shaft at approximately 10 cm from the joint margin and the matching line through the tibia 
5
. 
Sample Size The study was powered to show an incidence reduction from 20% in the DEP diet and exercise 
program control group and in the placebo group to 10% in the diet and exercise program DEP intervention and 
the glucosamine group. These numbers were based on a twelve year follow-up study with an overall incidence 
of K&L ≥ 2 of 39.1% in subject with a BMI ≥ 26.4 kg/m
2
 
6
. In the present age group, this number was 1.6 fold 
higher, suggesting an incidence of 13% over 2.5 years. The primary outcome combined incidence of K&L grade 
≥ 2, ACR criteria and JSN. Since there is only moderate overlap between these measures 
7
, a 20% incidence in 
the control group seemed reasonable. No interaction between the interventions was assumed. Based on rates 
in our previous 2-year osteoarthritis OA trial 
8
, we accounted for 10% lost to follow-up. Therefore, two groups of 
200 subjects would be appropriate (one-sided testing, alpha = 0.05, beta = 0.80). 
Statistical Analysis Intention To Treat (ITT) analyses on all available data of all knees of all randomized 
Figure(s)
participants served as primary analyses. First, the univariate association between known prognostic variables 
(age, K&L grade (≥1 vs. 0), varus alignment (<178° versus ≥178°) 
9
, mild knee symptoms (‘Did you experience 
knee pain in the past 12 months’), BMI, a history of knee injury, Heberden´s nodes, and postmenopausal status) 
and the primary outcome was determined using Generalized Estimating Equations (GEE), with the association 
between two knees within one person taken into account. Variables with a p-value < 0.2 were analysed 
multivariately. Variables with a p-value <0.05 in the multivariate model were adopted as confounders. Second, 
the interaction between both interventions was determined using GEE, adjusted for the confounding variables. 
Third, the effects of diet and exercise program DEP and GSvP the glucosamine vs. placebo intervention were 
determined using GEE, adjusted for the confounding variables. In case of a significant interaction between the 
interventions, these analyses will be performed over four groups, with subjects in the diet and exercise program 
DEP control group receiving placebo as reference group. 
For the pre-defined Per Protocol (PP) analyses, the latter two ITT analyses were rerun, between those 
subjects compliant to DEP the diet and exercise program (≥ 6 dietary consultations and ≥ 7 attended physical 
exercise classes) and those randomized to the DEP control group and, separately, in those with an objective 
compliance calculation ≥ 75% of the study drug throughout the study period. A sensitivity analysis excluding all 
knees fulfilling one of the criteria of the primary outcome at baseline was performed, and finally all analyses 
were repeated on a subject level. All analyses were performed using PASW statistics version 20.0 (SPSS Inc., 
Chicago, IL).  
Available secondary outcomes were analysed using a linear mixed model estimated by restricted 
maximum likelihood (REML) to test effects of both interventions and their interaction over the follow-up period 
(SAS 9.2, SAS Institute Inc., Cary, NC). A p-value < 0.05 was defined as statistically significant for all analyses. 
Randomization code for GSvP glucosamine vs. placebo intervention was broken after all analyses were 
completed. 
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Appendix Figure 1. Mean quality of life (EuroQol) scores within randomized intervention groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 2. Mean WOMAC pain scores (range 0 – 100; higher scores mean more pain) within 
randomized intervention groups. 
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Appendix Figure 3. Mean WOMAC function scores (range 0 – 100; higher scores mean less function) within 
randomized intervention groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 4. Actual weight loss (negative values represent weight gain from baseline) within randomized 
intervention groups. 
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Appendix Table 1. Odds ratios from sensitivity analyses (Intention To Treat), excluding knees already fulfilling 
one of the criteria of the primary outcome on baseline. 
 N 
(knees) 
Incident 
knee OA 
OR * 95% CI OR 
**
 
 
95% CI 
DEP control / placebo 186 16% 1 (reference) 1 (reference) 
DEP control / glucosamine 186 12% 0.73 0.37 – 1.45 0.72 0.36 – 1.44 
DEP intervention / placebo 179 13% 0.71 0.38 – 1.35 0.71 0.37 – 1.36 
DEP intervention / glucosamine 179 18% 1.15 0.61 – 2.17 1.12 0.59 – 2.14 
* unadjusted odds ratio. 
**
 odds ratio adjusted for baseline KL grade (0 vs. ≥ 1). DEP: diet and exercise program, 
OA: osteoarthritis, OR: odds ratio, CI: confidence interval. 
 
 
Appendix Table 2. Odds ratios from sensitivity analyses (Per Protocol for DEP), excluding knees already 
fulfilling one of the criteria of the primary outcome on baseline. 
 N 
(knees) 
Incident 
knee OA 
OR * 95% CI OR 
**
 
 
95% CI 
DEP control / placebo 186 16% 1 (reference) 1 (reference) 
DEP control / glucosamine 186 12% 0.73 0.37 – 1.45 0.71 0.35 – 1.45 
DEP intervention / placebo 56 9% 0.45 0.14 – 1.43 0.45 0.14 – 1.46 
DEP intervention / glucosamine 48 23% 1.52 0.68 – 3.41 1.63 0.72 – 3.65 
* unadjusted odds ratio. 
**
 odds ratio adjusted for baseline KL grade (0 vs. ≥ 1). DEP: diet and exercise program, 
OA: osteoarthritis, OR: odds ratio, CI: confidence interval. 
 
Appendix Table 3. Odds ratios from sensitivity analyses (Intention To Treat) at subject level. 
 N Incident 
knee OA 
*
 
OR 
**
 95% CI OR 
***
 
 
95% CI 
DEP control / placebo 102 29% 1 (reference) 1 (reference) 
DEP control / glucosamine 102 21% 0.58 0.30 – 1.13 0.64 0.32 – 1.26 
DEP intervention / placebo 101 28% 0.83 0.44 – 1.56 0.89 0.46 – 1.72 
DEP intervention / glucosamine 102 32% 1.04 0.56 – 1.93 1.20 0.63 – 230 
* 
defined as primary outcome in one or both knees. 
**
 unadjusted odds ratio. 
***
 odds ratio adjusted for baseline 
KL grade, varus alignment, and mild symptoms all defined as in 0 vs. ≥ 1 knee, and baseline BMI. DEP: diet and 
exercise program, OA: osteoarthritis, OR: odds ratio, CI: confidence interval. 
 
 
Appendix Table 4. Odds ratios from sensitivity analyses (Per Protocol for DEP) at subject level. 
 N Incident 
knee OA 
*
 
OR 
**
 95% CI OR 
***
 
 
95% CI 
DEP control / placebo 102 29% 1 (reference) 1 (reference) 
DEP control / glucosamine 102 21% 0.58 0.30 – 1.13 0.65 0.32 – 1.30 
DEP intervention / placebo 29 14% 0.31 0.10 – 0.96 0.31 0.09 – 1.06 
DEP intervention / glucosamine 28 39% 1.44 0.58 – 3.57 2.21 0.77 – 6.28 
* 
defined as primary outcome in one or both knees. 
**
 unadjusted odds ratio. 
***
 odds ratio adjusted for baseline 
KL grade, varus alignment, and mild symptoms all defined as in 0 vs. ≥ 1 knee, and baseline BMI. DEP: diet and 
exercise program, OA: osteoarthritis, OR: odds ratio, CI: confidence interval. 
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